Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8476281 | 0.82 | KDM4E (0.37) | PAOXKDM4E | |
| SCHEMBL8475429 | 0.82 | KDM4E (0.32) | KDM4E | |
| SCHEMBL11130773 | 0.75 | EPHX1 (0.44) | — | |
| SCHEMBL26452808 | 0.75 | PAOX (0.37) | PAOXKDM4E | |
| SCHEMBL21302052 | 0.72 | — | — | |
| SCHEMBL353945 | 0.71 | APP (0.33) | — | |
| SCHEMBL9221394 | 0.71 | TDP1 (0.47) | PAOXKDM4E | |
| SCHEMBL28154673 | 0.71 | ALDH1A1 (0.41) | PAOX | |
| SCHEMBL7035084 | 0.71 | — | — | |
| SCHEMBL7571763 | 0.70 | CA12 (0.43) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149947-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | Prelude Therapeutics, Incorporated (US) | 2023-03-22 | — | — | EP | claimed |
| CN-115698024-A | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia 1 (MCL-1) protein | 普莱鲁德疗法有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20230357275-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357275-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| EP-4149947-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | Prelude Therapeutics, Incorporated (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115698024-A | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia 1 (MCL-1) protein | 普莱鲁德疗法有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021231737-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357275-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | MCL1, BCL2A1, BCL2L1 | PAOX 3899/4885KDM4E 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.